Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Driehaus Capital Management LLC

Driehaus Capital Management LLC trimmed its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 17.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,986,111 shares of the company's stock after selling 625,392 shares during the period. Driehaus Capital Management LLC owned approximately 0.26% of Teva Pharmaceutical Industries worth $65,814,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Duquesne Family Office LLC increased its position in shares of Teva Pharmaceutical Industries by 530.1% during the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock valued at $198,303,000 after acquiring an additional 7,569,450 shares in the last quarter. Crestline Management LP purchased a new stake in Teva Pharmaceutical Industries in the 4th quarter worth about $1,220,000. Cutter Capital Management LP bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth about $12,891,000. Beverly Hills Private Wealth LLC bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth about $213,000. Finally, BNP Paribas increased its holdings in Teva Pharmaceutical Industries by 59.8% during the fourth quarter. BNP Paribas now owns 12,655 shares of the company's stock valued at $279,000 after buying an additional 4,737 shares during the period. 54.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on TEVA shares. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Finally, JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $21.00 to $23.00 in a research note on Monday. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $24.43.

Teva Pharmaceutical Industries Stock Up 5.8%

NYSE:TEVA traded up $0.99 during trading hours on Monday, hitting $17.92. 19,236,256 shares of the company traded hands, compared to its average volume of 10,066,102. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The company has a market cap of $20.31 billion, a PE ratio of -12.36, a PEG ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The firm's 50-day simple moving average is $15.18 and its 200-day simple moving average is $17.44.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The company's quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.48 earnings per share. Equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.